New approaches to the treatment of dense deposit disease.
The development of clinical treatment protocols usually relies on evidence-based guidelines that focus on randomized, controlled trials. For rare renal diseases, such stringent requirements can represent a significant challenge. Dense deposit disease (DDD; also known as membranoproliferative glomerulonephritis type II) is a prototypical rare disease. It affects only two to three people per million and leads to renal failure within 10 yr in 50% of affected children. On the basis of pathophysiology, this article presents a diagnostic and treatment algorithm for patients with DDD. Diagnostic tests should assess the alternative pathway of complement for abnormalities. Treatment options include aggressive BP control and reduction of proteinuria, and on the basis of pathophysiology, animal data, and human studies, plasma infusion or exchange, rituximab, sulodexide, and eculizumab are additional options. Criteria for treatment success should be prevention of progression as determined by maintenance or improvement in renal function. A secondary criterion should be normalization of activity levels of the alternative complement pathway as measured by C3/C3d ratios and C3NeF levels. Outcomes should be reported to a central repository that is now accessible to all clinicians. As the understanding of DDD increases, novel therapies should be integrated into existing protocols for DDD and evaluated using an open-label Bayesian study design.
Smith
Richard J H
RJ
Department of Internal Medicine and Otolaryngology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. richard-smith@uiowa.edu
Alexander
Jessy
J
Barlow
Paul N
PN
Botto
Marina
M
Cassavant
Thomas L
TL
Cook
H Terence
HT
de Córdoba
Santiago Rodriguez
SR
Hageman
Gregory S
GS
Jokiranta
T Sakari
TS
Kimberling
William J
WJ
Lambris
John D
JD
Lanning
Lynne D
LD
Levidiotis
Vicki
V
Licht
Christoph
C
Lutz
Hans U
HU
Meri
Seppo
S
Pickering
Matthew C
MC
Quigg
Richard J
RJ
Rops
Angelique L
AL
Salant
David J
DJ
Sethi
Sanjeev
S
Thurman
Joshua M
JM
Tully
Hope F
HF
Tully
Sean P
SP
van der Vlag
Johan
J
Walker
Patrick D
PD
Würzner
Reinhard
R
Zipfel
Peter F
PF
D000818:Animals; D003170:Complement Pathway, Alternative; D004195:Disease Models, Animal; D018450:Disease Progression; D015432:Glomerulonephritis, Membranoproliferative / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007668:Kidney / Q000473:pathology / Q000503:physiopathology